CBIO · Crescent Biopharma, Inc.
$16.59
+0.36 (+2.22%)
At close · Aug 21
Market Cap
$602.85M
Shares
37.14M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$10.84M
FY2025
Net Income
-$153.94M
-306.4%
FY2025
Operating Margin
-1407.52%
FY2025
Diluted EPS
-$59.00
-1.7%
FY2024
Operating Cash Flow
-$71.53M
-130%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $10.84M | — | $10K | $75K | $1.16M | $10.16M | — | $20M | — | $18.5K | $20.07M | $15.03M | $3.99M | $15.26M | |
| $152.67M | $138.09M | $14.26M | $20.07M | $28.39M | $47.49M | $44.93M | $47.03M | $40.09M | $24.1M | $23.28M | $25.05M | $19.57M | $11.7M | $9.44M | |
| $29.45M | $25.39M | $18.25M | $19.21M | $19.09M | $17.12M | $16.74M | $14.36M | $11.41M | $9.83M | $8.65M | $7.81M | $6.6M | $2.9M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $6.6M | $2.9M | $2.18M | |
| — | — | $7M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $182.12M | $163.48M | $40.04M | $39.29M | $47.48M | $64.61M | $61.67M | $61.39M | $51.5M | $33.93M | $31.93M | $32.86M | $26.17M | — | — | |
| -$168.47M | -$152.63M | -$40.04M | -$39.28M | -$47.4M | -$63.45M | -$51.51M | -$61.39M | -$51.5M | -$33.93M | -$31.91M | -$12.78M | -$11.14M | -$10.61M | $3.64M | |
| — | -1407.52% | — | -392752.93% | -63204.43% | -5470.69% | -506.84% | — | -257.52% | — | -172505.32% | -63.7% | -74.13% | -265.65% | 23.82% | |
| $0 | $2.19M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $2.16M | $2.38M | — | — | — | — | — | $651.21K | $103.65K | $15.33K | $18.24K | $894 | $20.99K | |
| — | -$151.94M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $2M | $2M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$96.03M | -$153.94M | -$37.88M | -$36.9M | -$46.69M | -$63.43M | -$51.03M | -$57.89M | -$48.27M | -$33.28M | -$31.81M | -$12.77M | -$11.12M | -$10.61M | $3.66M | |
| — | -1419.61% | — | -368994.2% | -62251.74% | -5468.98% | -502.09% | — | -241.37% | — | -171945.07% | -63.62% | -74.01% | -265.63% | 23.96% | |
| -$143.25M | -$133.45M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$165.12M | -$153.94M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | — | -$59.00 | -$58.00 | -$89.00 | -$123.00 | -$112.00 | -$134.00 | — | — | — | — | -$60.00 | -$887.00 | $393.00 |
| USD/shares | — | — | -$59.00 | -$58.00 | -$89.00 | -$123.00 | -$112.00 | -$134.00 | — | — | — | — | -$60.00 | -$887.00 | $33.00 |
| shares | — | — | 644.77K | 633.42K | 525.31K | 514.53K | 457.21K | 432.55K | 410.45K | 293.96K | 212.56K | 190.11K | 184.52K | 11.96K | 9296.19 |
| shares | — | — | 644.77K | 633.42K | 525.31K | 514.53K | 457.21K | 432.55K | 410.45K | 293.96K | 212.56K | 190.11K | 184.52K | 11.96K | 110.17K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.09×
EV/EBIT
—
Peer median 24.05×
P/E (TTM)
—
Peer median 13.02×
Peer medians compare against the 318 similar-size Biotechnology companies (of 546 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 |
|---|---|
| Reportable Segment | $10,844,000 |
Key facts
CIK
1253689
CUSIP
G2545C104
13F (30d)
77 filings
77 filers
Visit website
Investor relations